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Evolution of resistance towards antibiotics, or any other drug, can simultaneously increase (cross-resistance) or decrease (col-lateral sensitivity) fitness to multiple other drugs1–5. The molec-
ular mechanisms driving cross-resistance are well-described2,4,5. In 
contrast, it remains unclear how frequently genetic adaptation to a 
single drug increases bacterial sensitivity to other drugs and what 
the underlying molecular mechanisms of collateral sensitivity are. 
This issue is important as collateral sensitivity could direct future 
multidrug therapeutic strategies6. However, such strategies are lim-
ited by the scarcity of available drug pairs showing collateral sensi-
tivity that could also be used in clinical settings. Clearly, the concept 
of collateral sensitivity needs to be expanded by studying a broader 
scope of antimicrobial agents.
Here, we systematically study the effect of antibiotic-resistance 
mechanisms on susceptibility to antimicrobial peptides, a promis-
ing class of new antibacterial compounds. Antimicrobial peptides 
are short peptides with a broad spectrum of antibacterial activities7. 
Such peptides are found among all classes of life, and are part of the 
defence mechanisms against microbial pathogens7. Because antimi-
crobial peptides have diverse chemical features and cellular targets, 
they are promising antibacterial agents8,9. However, the degree of 
similarity between the resistance mechanisms to peptides and to 
small-molecule antibiotics remains disputed10. This is relevant as 
some peptides have now reached advanced stages in clinical trials8.
We had previously initiated laboratory evolutionary experi-
ments starting with a single clone of Escherichia coli K-122,3. Parallel 
evolving populations were exposed to gradually increasing concen-
trations of 1 of 12 clinically relevant antibiotics (Supplementary 
Table 1), leading to up to 328-fold increases in their minimum 
inhibitory concentrations (MICs) relative to the wild type2. The 
resistance levels were equal to or above the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) clinical break-
points, and 52% of the antibiotic-resistant strains showed resistance 
to multiple antibiotics2. Here, we focus on a representative set of 60 
antibiotic-resistant strains (5 strains per antibiotic) that have been 
subjected to whole-genome sequence analysis in order to identify 
the molecular mechanisms underlying antibiotic resistance2. Many 
of the observed mutations have also been detected in clinical drug-
resistant isolates, and are known to target cellular systems involved 
in inner and outer membrane transport and permeability (for 
example, efflux pumps, porins) and cell envelope biogenesis2.
We hypothesized that such membrane-altering antibiotic-resis-
tance mutations not only influence susceptibility to other antibiot-
ics, but to antimicrobial peptides as well. Why should this be so? 
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Antimicrobial peptides are promising alternative antimicrobial agents. However, little is known about whether resistance to 
small-molecule antibiotics leads to cross-resistance (decreased sensitivity) or collateral sensitivity (increased sensitivity) to 
antimicrobial peptides. We systematically addressed this question by studying the susceptibilities of a comprehensive set of 
60 antibiotic-resistant Escherichia coli strains towards 24 antimicrobial peptides. Strikingly, antibiotic-resistant bacteria show 
a high frequency of collateral sensitivity to antimicrobial peptides, whereas cross-resistance is relatively rare. We identify 
clinically relevant multidrug-resistance mutations that increase bacterial sensitivity to antimicrobial peptides. Collateral sen-
sitivity in multidrug-resistant bacteria arises partly through regulatory changes shaping the lipopolysaccharide composition of 
the bacterial outer membrane. These advances allow the identification of antimicrobial peptide–antibiotic combinations that 
enhance antibiotic activity against multidrug-resistant bacteria and slow down de novo evolution of resistance. In particular, 
when co-administered as an adjuvant, the antimicrobial peptide glycine-leucine-amide caused up to 30-fold decrease in the 
antibiotic resistance level of resistant bacteria. Our work provides guidelines for the development of efficient peptide-based 
therapies of antibiotic-resistant infections.
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The action of most antimicrobial peptides relies on the interaction 
between the positively charged peptide and the negatively charged 
membrane components, for two reasons. First, the structural and 
physicochemical properties of antimicrobial peptides (for example, 
net positive charge, hydropathicity) and their capacity to adopt an 
amphipathic conformation upon membrane binding influence this 
interaction8,11,12. Second, the insertion of antimicrobial peptides 
into the hydrophobic core of the membrane depends on the general 
properties of the bacterial outer membrane11,12. For instance, lipo-
polysaccharide (LPS) composition has a major impact on the killing 
efficiency of cationic antimicrobial peptides13. For these reasons, it is 
plausible that membrane-affecting antibiotic-resistance mutations 
shape genetic susceptibility to antimicrobial peptides. However, no 
systematic study has been devoted to address this problem in detail.
Here, we first measured the susceptibility of the 60 antibiotic-
resistant strains2,3 against a set of 24 antimicrobial peptides of diverse 
origin and various modes of action. We found widespread bacterial 
collateral sensitivity towards antimicrobial peptides. Analysis of the 
mutational and transcriptome profiles of the antibiotic-resistant 
strains revealed that antibiotic-resistance mutations increase sensi-
tivity to peptides via regulatory changes in LPS biosynthesis. The 
consequent alteration in the surface charge presumably strengthens 
the interaction of cationic antimicrobial peptides with the outer 
membrane, and thus enhances the killing efficiency of these pep-
tides. Finally, we demonstrated that the antimicrobial peptide gly-
cine-leucine-amide (PGLA), when co-administered as an adjuvant, 
restores antibiotic activity against resistant bacteria and slows down 
antibiotic-resistance evolution.
Results
Widespread collateral sensitivity to antimicrobial peptides. To 
study whether antibiotic resistance in E. coli leads to cross-resis-
tance or collateral sensitivity towards antimicrobial peptides, we 
measured the changes in the susceptibilities of 60 antibiotic-resis-
tant strains to a set of 24 peptides. Peptides were chosen based on 
the following criteria: diverse sources (synthetic/natural), different 
putative mechanisms of action, structural diversity, and clinical rel-
evance (Supplementary Table 2). The obtained results allowed us to 
chart the map of cross-resistance/collateral sensitivity of the anti-
biotic-resistant strains towards the 24 antimicrobial peptides, and 
identify several general patterns (Fig. 1a, Supplementary Table 3).
First, cross-resistance to antimicrobial peptides was relatively 
rare: only 12% of all possible antibiotic-resistant strain and pep-
tide pairs showed cross-resistance, whereas 31% showed collateral 
sensitivity. The observed strength of cross-resistance and collateral 
sensitivity was usually a twofold change in MIC relative to the wild 
type (Supplementary Fig. 1, Supplementary Table 4). In typical clin-
ical settings, drug concentrations well above the wild-type MIC are 
applied14. Therefore, we asked how collateral sensitivity shapes the 
killing kinetics with peptides applied at a concentration 10–15-fold 
above the wild-type MIC. We focused on five resistant strains that 
showed collateral sensitivity to at least one of the peptides studied 
(Fig. 2a–c). Upon antimicrobial peptide stress, collateral-sensitive 
populations showed a far more rapid decline in size than the wild 
type. For example, 15 minutes of protamine (PROA) exposure 
nearly completely eradicated ciprofloxacin (CPR)-resistant bacte-
ria, whereas the size of the wild-type population declined only by 
tenfold (Fig. 2a).
Second, collateral sensitivity and cross-resistance patterns clus-
tered the antimicrobial peptides into three main groups (Fig. 1) 
with major differences in their physicochemical properties and 
modes of action. Antimicrobial peptides belonging to the P1 and 
P3 groups generally insert themselves into membrane bilayers to 
form pores and thus induce cell lysis (pore formers). However, 
these two groups differ both in their physicochemical properties 
and their interactions with antibiotic-resistant strains: P1 peptides 
have lower isoelectric point and hydropathicity index compared 
to P3 peptides (see Supplementary Fig. 2) and are depleted in 
cross-resistance and collateral sensitivity interactions, whereas 
collateral sensitivity towards P3 peptides is prevalent (Fig. 1a, 
Supplementary Table 5).
On the contrary, members of the P2 group typically penetrate 
into the cell and have intracellular targets (Supplementary Table 2). 
Unlike P1 and P3, the P2 group consists of proline-rich peptides 
that are characterized by unstable secondary peptide structure, 
high propensity for aggregation in aqueous solutions and relatively 
low aliphatic and hydropathicity indices (Supplementary Fig. 3, 
Supplementary Table 6). Notably, cross-resistance towards P2 pep-
tides is frequent compared to the other peptide groups (Fig. 1a, 
Supplementary Table 5).
Third, not all peptides were equally effective against antibiotic-
resistant bacteria (Fig. 1b). Most notably, 82% of the antibiotic-
resistant strains showed collateral sensitivity to PGLA, a member 
of the magainin family15 (Fig. 1c). Consistent with their conserved 
evolutionary roles, human peptides, such as human beta defensin 
3 (HBD3) and LL-37 cathlecidin (LL37), also showed few, if any, 
cross-resistance interactions (Fig. 1b, Supplementary Table 3). In 
contrast, various antibiotic-resistant strains showed cross-resistance 
to the proline-rich peptide apidaecin IB (AP). This result could 
be of clinical relevance, as AP is currently being investigated for 
therapeutic usage16.
We next tested the evolutionary conservation of collateral sen-
sitivity by measuring the susceptibility of clinically-derived E. coli 
strains towards nine relevant antimicrobial peptides. Three clinical 
isolates were previously allowed to adapt to three different antibiot-
ics (gentamicin, nalidixic acid (NAL) and ampicillin (AMP)) in the 
laboratory1. The peptide susceptibility profiles of these antibiotic-
resistant strains showed good agreement with those presented in 
Fig. 1, indicating that collateral sensitivity is partly conserved across 
multiple genetic backgrounds (Supplementary Table 7).
Aminoglycoside resistance induces cross-resistance to anti-
microbial peptides. Whereas cross-resistance to antimicrobial 
peptides was generally much less common than collateral sensitiv-
ity, the distribution of cross-resistance interactions was far from 
random (Fig. 1c). Specifically, strains resistant to aminoglyco-
sides (tobramycin (TOB) and kanamycin (KAN)) showed cross- 
resistance to proline-rich peptides (P2 group, see Fig. 1a). These 
strains are reminiscent of aminoglycoside-resistant small-colony 
variants observed in clinical settings, as they accumulated mem-
brane potential-altering mutations17. Moreover, they uniquely car-
ried a loss-of-function mutation in the gene encoding the inner 
membrane transport protein sbmA2 (Fig. 1a). sbmA is commonly 
mutated in response to aminoglycoside stress18, and is involved in 
the uptake of proline-rich peptides10,19.
Here, we asked whether a loss-of-function mutation in sbmA 
contributes to the observed cross-resistance pattern of the ami-
noglycoside-resistant strains against P2 peptides. As expected, 
deletion of this gene in E. coli BW25113 and in the clinical isolate 
E. coli ATCC 25922 conferred mild, but significant, resistance to both 
aminoglycosides and proline-rich peptides (Table 1, Supplementary 
Text 1, Supplementary Fig. 4a–f). For a possible contribution of 
other mutations to cross-resistance between aminoglycosides and 
proline-rich peptides, see Supplementary Text 2.
Multidrug-resistance mutations confer collateral sensitivity to 
antimicrobial peptides. We next explored the mutations underly-
ing collateral sensitivity. To this end, we first clustered the antibi-
otic-resistant strains based on their peptide susceptibility profiles 
and compiled the set of mutations shared among them (Fig. 1a). 
This procedure revealed four main groups of resistant strains 
(S1–S4), each of them carrying distinct sets of mutations.
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Fig. 1 | Susceptibility profiles of 60 laboratory-evolved antibiotic-resistant E. coli strains. a, Hierarchical clustering of 60 antibiotic-resistant strains 
(rows) and a set of 24 antimicrobial peptides (columns) based on the cross-resistance and collateral sensitivity interactions between them (for 
abbreviations of antibiotics and antimicrobial peptides see Supplementary Tables 1 and 2, respectively). Hierarchical clustering was performed separately 
on rows and columns, using Ward’s method67. Black squares on the right side of each antibiotic-resistant strain denote previously identified mutations 
in antibiotic-resistance genes2,3 that were significantly enriched in one or more strain clusters (P <  0.05, two-sided Fisher’s exact test). S1 strains were 
enriched in envZ, ompR and ompC mutations, whereas S3 strains were enriched in marR mutations (P <  0.05 for all cases, two-sided Fisher’s exact test). 
While S3 strains show widespread collateral sensitivity to antimicrobial peptides, especially to P1 and P3 peptides, aminoglycoside-resistant strains 
(S4) show extensive cross-resistance to proline-rich peptides (P2) (P <  0.0001, two-sided Fisher’s exact test). b, Efficiency of antimicrobial peptides 
against antibiotic-resistant bacteria expressed as the percentage of strains showing collateral sensitivity (blue), no interaction (white) or cross-resistance 
(orange) against each peptide. A total of 56–60 strains per antimicrobial peptide were employed for the analysis. c, Relative frequency of collateral 
sensitivity and cross-resistance interactions towards antimicrobial peptides upon adaptation to single antibiotics (n =  5 strains per antibiotic). The 
frequency of interactions for each peptide was calculated by counting the number of cross-resistance (orange), no interaction (white) and collateral 
sensitivity (blue) interactions displayed by all strains adapted to a given antibiotic. Antibiotic modes of action are shown on the top of the figure. 30SAG 
refers to aminoglycosides. Asterisks (*) mark significant deviations from hypergeometric distribution models calculated from all the interactions of 
all peptide-strain combinations separately for cross-resistance and collateral sensitivity, respectively. Strains adapted to DOX and TET were depleted, 
whereas strains adapted to TOB and KAN were enriched in cross-resistance interactions towards peptides (P =  0.005, P <  0.008, P =  0.003 and P <  0.001, 
respectively, two-sided Fisher’s combined probability test). Furthermore, strains adapted to ERY and TRM were significantly depleted in collateral 
sensitivity interactions (P =  0.003 and P <  0.001, respectively, two-sided Fisher’s combined probability test).
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Strains belonging to group S1 were adapted to a range of dif-
ferent antibiotics, including cefoxitin (FOX), a cell-wall inhibitor, 
and nitrofurantoin (NIT) that targets several biochemical processes 
within the bacterial cell. However, they mostly exhibited collateral 
sensitivity to P3 peptides (Fig. 1a) and accumulated mutations in 
a similar set of genes. Enrichment analysis revealed that they typi-
cally carry mutations in the EnvZ/OmpR two-component regula-
tory system and in the outer membrane porin C (ompC)2; for details 
and statistics, see Fig. 1a. The EnvZ/OmpR system, through regu-
lating the outer membrane porin genes ompC and ompF, mediates 
bacterial defence against antimicrobials by reducing the uptake of 
hydrophilic antibiotics20,21. Consistent with a causal role in collat-
eral sensitivity, inserting an ompC loss-of-function mutation into 
wild-type E. coli conferred resistance to NIT and cell-wall inhibi-
tor antibiotics, and simultaneously increased sensitivity to multiple 
antimicrobial peptides (see Table 1 and Supplementary Text 3 for a 
proposed mechanism).
We further identified a group of strains (S3, see Fig. 1a) that typi-
cally showed collateral sensitivity to pore-forming peptides (clusters 
P1 and P3). These strains carry mutations in marR, a transcriptional 
repressor of antibiotic stress response22 (Fig. 1a). MarR represses the 
mar regulon that controls genes involved in membrane permeabil-
ity and efflux of toxic chemicals23. Elevated expression of the mar 
regulon is frequently found in multidrug-resistant clinical isolates23. 
Insertion of a recurrently observed marR mutation2 either into 
wild-type E. coli BW25113 or into the antibiotic-sensitive clinical 
isolate E. coli ATCC 25922 conferred mild, but significant, resis-
tance to several antibiotics, and simultaneously enhanced sensitivity 
to P3 antimicrobial peptides (Table 1, Fig. 2d, Supplementary 
Text 1, Supplementary Fig. 4g–j).
Overall, these findings demonstrate that collateral sensitivity to 
antimicrobial peptides is induced by multidrug-resistant mutations 
that appeared repeatedly in response to various antibiotic stresses 
(for further examples, see Table 1).
Gene expression changes in LPS biosynthesis contribute to col-
lateral sensitivity. We next hypothesized that changes in the outer 
membrane composition of antibiotic-resistant bacteria underlie the 
observed collateral sensitivity to antimicrobial peptides.
To test this possibility, we started by determining the sensitivity 
of the antibiotic-resistant strains to bile acid, a membrane-damag-
ing agent. As expected, 75% of the antibiotic-resistant strains were 
more susceptible to bile acid than the wild type, and the bile acid-
sensitive strains showed collateral sensitivity to an especially high 
number of antimicrobial peptides (Fig. 3a). To explore the common 
mechanistic basis of this pattern, we compared the transcriptome 
profiles of the wild type and 24 antibiotic-resistant strains covering 
all 12 investigated antibiotics (see Methods). All strains were grown 
in antibiotic-free medium to ensure comparability between strains 
that display vastly different resistance levels.
Several lines of evidence support the hypothesis that antibiotic 
resistance leads to alterations in outer membrane composition. 
In 75% of the analysed antibiotic-resistant strains, transcriptional 
changes are significantly enriched in LPS- and outer membrane-
related genes (Fig. 3c, left panel), including genes involved in LPS 
biosynthesis and phospholipid binding and transfer. Importantly, 
strains with an especially high number of upregulated LPS-related 
genes (Supplementary Tables 8 and 9) display an enhanced sus-
ceptibility to bile acid (Fig. 3b). Finally, strains with upregulated 
genes in membrane-related functions were more likely to show 
collateral sensitivity to specific antimicrobial peptides (Fig. 3c and 
Supplementary Fig. 5).
Chemogenomic analysis of collateral sensitivity. To directly 
investigate the causality between upregulation of membrane-related 
genes and collateral sensitivity, we carried out a chemogenomic 
screen to identify genes that, when overexpressed, sensitize E. coli 
to the membrane-interacting 18-kDa cationic antimicrobial peptide 
(CAP18). CAP18 is an ideal choice for two reasons. First, it dis-
places divalent cations in the LPS layer and thereby permeabilizes 
the outer membrane24. Second, strains that are sensitive to CAP18 
displayed upregulation of genes involved in LPS biosynthesis, 
and phospholipid binding and transport (Fig. 3c, Supplementary 
Tables 8 and 9).
The chemogenomic screen of CAP18 was carried out by apply-
ing an established plasmid collection overexpressing all E. coli 
open reading frames (ORFs)25 in a pooled fitness assay with a 
deep sequencing readout (for details see Supplementary Fig. 6). 
Following growth of the pooled collection both in the presence and 
absence of CAP18, we identified genes that produce a growth defect 
when overexpressed in CAP18 treatment only (see Supplementary 
Fig. 6c). Such growth defects indicate increased CAP18 sensitivity 
upon overexpression of single genes. As a control, we performed 
the same assay on cecropin P1 (CP1), a peptide to which antibi-
otic-resistant strains rarely show collateral sensitivity (Fig. 1b). 
Our chemogenomic screen revealed 624 and 258 sensitizing genes 
for CAP18 and CP1, respectively (see Supplementary Table 10). 
As expected, LPS-related genes were highly enriched among genes 
that sensitize to CAP18, but not to CP1, when overexpressed 
(Supplementary Table 11). For example, LPS biosynthesis genes 
were especially likely to sensitize the bacteria to CAP18 when 
overexpressed (odds ratio = 4.4, P = 0.004, two-sided Fisher’s exact 
test). Furthermore, CAP18-sensitizing LPS biosynthesis genes, as 
inferred by chemogenomics, showed higher average expression 
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Fig. 2 | Survival of collateral-sensitive antibiotic-resistant strains under 
lethal antimicrobial peptide stress. a–c, The wild-type and antibiotic-
resistant strains were exposed to high concentrations of antimicrobial 
peptides: the TET-resistant TET3 and the CPR-resistant CPR7 strains were 
exposed to 15-fold (3,000 μ g ml−1) MIC of PROA (a); the CPR-resistant 
CPR7 and the TOB-resistant TOB8 were exposed to 10-fold MIC  
(125 μ g ml−1) of IND (b); and the DOX-resistant DOX3 and the KAN-
resistant KAN8 were exposed to 15-fold MIC (1,500 μ g ml−1) of PGLA (c). 
All antibiotic-resistant strains exhibited collateral sensitivity towards the 
applied peptide. d, A strain containing a single point mutation in marR 
(marR*) was also exposed to 15-fold MIC of PGLA. This strain exhibits 
resistance to multiple antibiotics and collateral sensitivity to many of the 
peptides tested, including PGLA (Table 1). Cells were incubated with the 
particular peptide for 120 minutes. Samples were taken at defined time 
points and plated in lysogeny broth agar plates. Percentage of survival was 
calculated by counting the colony forming units (CFUs). Each data point 
shows the mean ±  s.e.m. of three biological replicates.
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levels in those antibiotic-resistant strains that are sensitive to CAP18 
compared to the rest (P = 0.008, two-sided Wilcoxon rank-sum 
test, Fig. 3d). We note that, although also frequently upregulated in 
CAP18-sensitive strains (Fig. 3c), genes with phospholipid-related 
functions were not enriched among sensitizing genes in the che-
mogenomic screen (Supplementary Table 11). Taken together, these 
analyses indicate that altered LPS biosynthesis plays a causal role in 
the widespread collateral sensitivity of antibiotic-resistant strains to 
antimicrobial peptides.
A marR mutation induces collateral sensitivity. We next deci-
phered a mechanistic link between a specific regulatory mutation 
and its impact on antibiotic resistance and collateral sensitivity. We 
focused on marR, as mutation in this gene affects bacterial response 
to antimicrobials in two opposite ways: it increases resistance to 
multiple antibiotics, but simultaneously sensitizes to membrane-
interacting peptides (Table 1). Why is this so?
LPS is a major component of the bacterial outer membrane that 
stabilizes the membrane structure, regulates its permeability and 
contributes to its negative charge26. The mar regulon is known to 
mediate LPS modification by positively regulating WaaY, a kinase 
responsible for phosphorylation of the inner core of LPS, lead-
ing to an increased negative surface charge of the bacterial outer 
membrane27,28 (Fig. 4). As an increased negative surface charge of 
the membrane generally promotes antimicrobial peptide killing 
efficiency9,27, upregulation of waaY is expected to enhance bacterial 
susceptibility to peptides.
Based on these facts, we hypothesized that mutations in marR 
increase antimicrobial peptide susceptibility through upregulation 
of waaY. Such upregulation should lead to an increase in phosphory-
lation of LPS and, as a consequence, elevated negative surface charge 
of the bacterial outer membrane (Fig. 4). Several lines of evidence 
support this hypothesis. First, the antimicrobial peptide susceptibil-
ity profiles of the marR single-mutant and the waaY-overexpressing 
strain showed substantial overlap (Table 1). Second, gene expression 
analysis using reverse-transcription quantitative PCR (RT–qPCR) 
confirmed that waaY is nearly fourfold upregulated in the marR 
single-mutant strain when compared to the wild type (fold change: 
3.88 ± 0.026 s.e.m., see Methods). Third, we carried out zeta poten-
tial measurements and demonstrated that both the marR mutant 
and the waaY-overexpressing strain display relatively high negative 
surface charge compared to the wild type (Supplementary Fig. 7). 
Finally, inactivation of waaY abolished collateral sensitivity to P3 
peptides in marR mutants (Supplementary Fig. 8). To summarize, 
these results indicate that collateral sensitivity of the marR mutant 
to peptides occurs via modulation of the LPS phosphorylation path-
way. We propose that the consequent altered outer membrane com-
position facilitates the interaction of antimicrobial peptides with the 
cell membrane and thereby enhances their killing efficiency (Fig. 4).
Peptide PGLA restores antibiotic activity in antibiotic-resistant 
bacteria. The above results have important implications for future 
development of drug combinations. Recently, two complementary 
mechanisms were proposed to contribute to the selective eradica-
tion of drug-resistant bacteria29. First, resistance to one drug can 
induce hypersensitivity to the other (collateral sensitivity, see also 
Supplementary Text 4)1,2 and, second, interactions can become 
more synergistic with the evolution of resistance, making the 
mutant more sensitive to the combination (resistance mutation-
induced synergy)30.
We focused on PGLA for two reasons. First, it shows an excep-
tionally high number of collateral sensitivity interactions (Fig. 1). 
Second, when used in combination, antibiotic-PGLA pairs show 
strong synergism in antibiotic-resistant, but not in the corre-
sponding wild-type, bacteria (Fig. 5a–d, Supplementary Table 12). 
Remarkably, strong synergism is prevalent in antibiotic-resistant 
strains carrying mutations in marR, envZ or ompF. As these genes 
influence membrane permeability, we speculate that PGLA may 
interfere with the activity of multidrug efflux systems and/or porins 
responsible for the observed antibiotic resistance in these strains.
We then tested whether PGLA could be used as an adjuvant and 
selectively potentiate antibiotic activity against antibiotic-resistant 
Table 1 | Selected individual mutations and their susceptibility profiles across antimicrobial peptides and antibiotics
Relative MIC change
P3 P2 P1
Gene Mutation PGLA HBD3 SB IND D28 PR39 CAP18 PROA AP PyR BAC5 CEME LL37 TPII CP1
ompC Met1Ile 0.7a 0.6a 1.0c 1.0c 0.7a 1.0c 0.8a 0.8a 0.8a 0.8a 1.0c 0.8a 1.0c 1.0c 1.0c
trkH Thr350Lys 0.7a 2.5b 1.0c 0.8a 0.8a 1.2b 1.0c 1.4b 0.6a 0.6a 1.2b 1.0c 1.0c 1.0c 1.0c
sbmA Deletion 0.8a 0.8a 0.8a 0.8a 1.0c 1.3b 1.0c 1.3b 2.0b 3.6b 1.8b 1.2b 1.0c 1.2b 1.0c
marR Val84Glu 0.6a 0.7a 0.7a 0.8a 1.0c 1.0c 0.8a 0.8a 1.4b 1.0c 1.0c 0.8a 1.0c 1.2b 1.0c
waaY Overexpression 1.0c 0.7a 0.8a 0.8a 0.8a 1.0c 0.8a 1.0c 2.0b 1.4b 1.0c 0.8a 1.0c 1.0c 1.0c
Relative MIC change
Cell wall Gyrase Multiple 50 s 30 s Folic 
acid
Aminoglycoside
Gene Mutation AMP FOX CPR NAL NIT CHL ERy DOX TET TRM TOB KAN
ompC Met1Ile > 5b 1.2b 0.7a 0.8a 1.2b 0.7a 1.0c 1.0c 1.0c 1.0c 1.0c 1.0c
trkH Thr350Lys 0.5a 0.8a 0.6a 0.3a 0.8a 0.6a 0.9a 0.5a 0.5a 0.6a 3.4b 2.1b
sbmA Deletion 1.0c 1.0c 1.0c 1.0c 1.0c 0.7a 1.0c 1.2b 1.2b 1.0c 1.3b 1.5b
marR Val84Glu 2.0b 3.3b 1.9b 2.1b 1.0c 2.2b 2.0b 1.9b 1.8b 1.3b 1.0c 1.0c
waaY Overexpression 1.4b 1.0c 1.2b 1.2b 0.5a NA 1.2b 1.0c 1.0c 1.4b 1.7b 2.0b
The selected mutations repeatedly occurred in different antibiotic-resistant strains. Each mutation was inserted back into the wild-type strain separately. Relative change in MIC was calculated as the ratio 
between the MIC of the compound on the mutant strain and on the wild-type strain. Values lower, higher and equal to one represent acollateral sensitivity, bcross-resistance or cno interaction, respectively. 
Data on antibiotic susceptibility are based on results previously published in case of the envZ, marR and trkH mutants2. NA, not available. For antibiotic and antimicrobial peptide abbreviations, see 
Supplementary Tables 1 and 2.
NATURE MICROBIOLOGy | VOL 3 | JUNE 2018 | 718–731 | www.nature.com/naturemicrobiology722
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
ArticlesNATure MICrObIOlOgy
bacteria. We tested CPR-, NAL-, tetracycline (TET)- and doxycy-
cline (DOX)-resistant E. coli, including laboratory-evolved strains 
(Fig. 5e–g) and clinical isolates (Fig. 5h–j, Supplementary Fig. 9). 
The dataset was also augmented with NAL-resistant Klebsiella 
pneumoniae and Shigella flexneri isolates (Supplementary Fig. 10). 
PGLA was administered at subinhibitory concentrations; that is, 
it allowed growth of the wild-type and the antibiotic-resistant 
strains alike. Strikingly, when used in combination, PGLA caused 
up to 30-fold decrease in the antibiotic resistance level of the 
resistant strains (Fig. 5e–g, Supplementary Figs. 9 and 10, and 
Supplementary Table 13). We conclude that PGLA can restore anti-
biotic susceptibility against resistant bacteria when administered 
as an adjuvant.
PGLA inhibits de novo evolution of resistance to antibiotics. 
Finally, we asked whether concurrent administration of antibiotics 
with subinhibitory dosages of PGLA hinders de novo resistance 
evolution in the laboratory (Fig. 6). To this end, we focused on two 
antibiotic-peptide combinations, CPR-PGLA and TET-PGLA. We 
evolved the wild-type E. coli strain in the presence of these anti-
biotic-PGLA combinations and their corresponding single drug 
components. The protocol aimed to maximize the level of antibiotic 
resistance in the evolving populations during a fixed time period. 
For each of the eight drug conditions, ten parallel bacterial lineages 
were evolved (Methods).
After only 160 generations, bacterial populations evolving in the 
presence of a single antibiotic reached 40- and 390-fold increases 
in TET and CPR MIC levels relative to their ancestor, respectively 
(Fig. 6a,b). Reassuringly, collateral sensitivity to PGLA arose in 
these lineages (Fig. 6d,e). In contrast, antibiotic-PGLA co-treat-
ment significantly slowed down the evolution of antibiotic resis-
tance. In the presence of subinhibitory dosages of PGLA, the level of 
c
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antibiotic resistance reached during the course of laboratory evolu-
tion was tenfold lower than in the absence of PGLA, and it remained 
consistently below the suggested EUCAST clinical breakpoints 
(Fig. 6a,b). In addition, evolution of resistance to PGLA was mar-
ginal (Fig. 6d,e). Reassuringly, no substantial cross-resistance was 
observed between PGLA and the antibiotics CPR or TET (Fig. 6). 
These patterns are not due to variations in population size across 
treatments (Supplementary Fig. 11).
We suspect that the efficiency of the antibiotic-PGLA co-treat-
ment reflects an elevated fitness cost of antibiotic resistance muta-
tions under such conditions. In other words, collateral sensitivity 
to PGLA may reduce the number of available resistance-conferring 
mutations under CPR-PGLA or TET-PGLA co-treatment (see also 
Supplementary Fig. 12). A full answer to this question will require 
detailed molecular and phenotypic characterization of laboratory-
evolved bacteria. As a preliminary test, we used the drug pair 
TOB-bactenecin 5 (BAC5), as TOB-resistant strains showed cross-
resistance rather than collateral sensitivity to the peptide BAC5 
(Fig. 1). As expected, the TOB-BAC5 combination did not reduce 
the rate of antibiotic resistance evolution (Fig. 6c,f).
Discussion
How do mutations conferring antibiotic resistance change the sus-
ceptibility to antimicrobial peptides? This question is all the more 
relevant as antimicrobial peptides are promising antibacterial alter-
natives to antibiotics currently used in the clinics8,9. In this work, 
we applied an integrated approach to study the susceptibilities of 
antibiotic-resistant E. coli strains towards antimicrobial peptides.
First, we found that antibiotic-resistant bacteria generally exhibited 
collateral sensitivity (increased susceptibility) to antimicrobial pep-
tides, while cross-resistance was relatively rare. Several prior works 
have investigated cross-resistance and collateral sensitivity interac-
tions between conventional antibiotics1–3,31,32. Despite substantial 
differences in the protocols, these systematic studies agreed that 
cross-resistance is generally 2–3 times more frequent than collateral 
sensitivity. By contrast, we see nearly three times more collateral sen-
sitivity than cross-resistance towards antimicrobial peptides (Fig. 1).
Second, although we studied bacteria adapted to a diverse set 
of antibiotics with major differences in their mechanisms of action 
(Supplementary Table 1), bacterial susceptibilities to antimicro-
bial peptides revealed several general trends. This is partly due to 
mutations in canonical resistance genes that emerged repeatedly in 
response to various antibiotic stresses. By introducing these muta-
tions into a wild-type genetic background, we showed that muta-
tions conferring resistance to one or more antibiotics simultaneously 
increase sensitivity to several antimicrobial peptides (Table 1). 
The most noteworthy example is the transcriptional repressor of the 
mar regulon (marR). Mutations in this gene are frequently observed 
both in the laboratory and in clinical settings, and increase resis-
tance to multiple unrelated antibiotics2,22. Here, we showed that a 
mutation in this gene increases the negative surface charge of the 
bacterial outer membrane (Supplementary Fig. 7) and, eventually, 
leads to elevated susceptibility to several antimicrobial peptides.
More generally, our findings indicate that susceptibility to anti-
microbial peptides arises as a by-product of genomic expression 
changes in antibiotic-resistant bacteria (Fig. 3), presumably because 
these alterations modify the chemical structure of the bacterial 
outer membrane. Importantly, these conclusions do not hold for all 
combinations of antimicrobial peptides and resistant bacteria stud-
ied. Most notably, aminoglycoside-resistant bacteria accumulated a 
distinct set of mutations showing practically no overlap with other 
laboratory-evolved antibiotic-resistant bacteria2. They uniquely 
carried deleterious mutations in the gene encoding the inner mem-
brane transport protein sbmA2,3. This mutation delivered resis-
tance to proline-rich peptides and aminoglycosides as well (Fig. 1  
and Table 1).
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These considerations could be important for the development 
of combination therapies. The fact that antibiotic-resistant strains 
showed extensive collateral sensitivity to certain antimicrobial 
peptides led us to study one of them, PGLA, in more detail. We 
identified two important properties of PGLA. First, antibiotic 
resistance generally resulted in collateral sensitivity to this pep-
tide (Fig. 1) and, second, antibiotic-PGLA combinations induced 
synergism in certain antibiotic-resistant bacteria (resistance muta-
tion-induced synergy, Fig. 5a–d). Based on these properties, we 
hypothesized that PGLA could be used for the eradication of drug-
resistant bacteria as well as the inhibition of de novo resistance 
evolution. When used in combination, a subinhibitory dose of 
PGLA caused up to 30-fold increase in susceptibility in antibiotic-
resistant bacteria (Fig. 5e–j). Furthermore, co-administration of 
the same subinhibitory dose of PGLA efficiently slowed down the 
evolution of antibiotic resistance and kept resistance levels under 
the EUCAST breakpoints (Fig. 6). Future works should examine 
whether such a combination strategy can be maintained over lon-
ger time scales without the appearance of resistance mutations that 
diminish the antibiotic-PGLA synergy33. Needless to say, we only 
consider PGLA as a first step towards the development of an adju-
vant therapy. By studying the structural and functional properties 
of promising antimicrobial peptides, peptidomimetic molecules 
could be developed that are less prone to resistance, stable against 
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Fig. 5 | Interaction of PGLA and antibiotics when applied in combination. Antibiotic–PGLA interactions were determined in E. coli K-12 BW25133 wild-
type and corresponding antibiotic-resistant strains. For antibiotic abbreviations see Supplementary Table 1. a–d, The combination effect of PGLA and 
CPR or TET on the wild-type strain (a and c), CPR-resistant strain (CPR7) (b) and TET-resistant strain (TET3) (d). While the combination shows strong 
antagonism (a) or no interaction (c) in the wild-type strain, the interaction shifted to strong synergism in the resistant strain (b and d). Dashed line 
represents no interaction calculated based on the Loewe additivity model (see Methods). Growth rate is represented in the combination space by the 
shade of the grey colour with darker shades denoting higher growth rates. e–j, The effect of subinhibitory concentrations of PGLA on antibiotic activity. 
CPR-resistant CPR7 (e), TET-resistant TET3 (f) and DOX-resistant DOX3 (g) strains, derived from E. coli K-12 BW25133, were treated with subinhibitory 
concentrations of PGLA, while measuring the MIC for the given antibiotic to which they were adapted. The concentrations of PGLA used were 1/16, 1/8, 
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PGLA). Dashed lines represent the clinical breakpoints for the antibiotics in E. coli (not available for DOX). Data in this figure are representative of at least 
two biological replicates. CI, combination index.
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human proteases8,34 and efficient against a broad range of drug-
resistant pathogens.
An important unresolved issue is whether collateral-sensitive 
peptide–antibiotic combinations could also be employed sequen-
tially to select against resistance. This strategy, termed collateral 
sensitivity cycling, has remained controversial1,35. Our preliminary 
results indicate that the two key ingredients of this strategy are pres-
ent. First, evolving resistance to an antimicrobial peptide (CAP18) 
results in collateral sensitivity to several conventional antibiotics, 
and this collateral sensitivity is reciprocal (Supplementary Fig. 13). 
Second, both antibiotic- and CAP18-resistant bacteria can be selec-
tively eradicated by deploying the collateral-sensitive drug partner 
(Supplementary Fig. 14).
Last, we need to emphasize the limitations of our work. The 
molecular mechanisms underlying collateral sensitivity need to be 
addressed in more detail. It also remains to be established whether 
antimicrobial peptide–antibiotic combinations generally outper-
form conventional antibiotic combinations in their ability to hinder 
resistance evolution. At best, we made the first step in these direc-
tions. An important objection to clinical usage of antimicrobial pep-
tides is that acquisition of resistance against synthetic antimicrobial 
peptides could drive cross-resistance towards antimicrobial peptides 
of the host innate immune system36,37. While this is certainly a real-
istic danger—at least in laboratory settings—two notes must be 
made. First, the diverse susceptibility profiles of antibiotic-resistant 
strains towards antimicrobial peptides (Fig. 1) confirm major dif-
ferences both in the mechanisms of action of antimicrobial peptides 
and the potential routes to antimicrobial peptide resistance. Second, 
our data indicate that certain peptide–antibiotic combinations 
could select against the de novo evolution of resistance against both 
agents (Fig. 6).
In summary, our work establishes that antibiotic-resistant bacte-
ria frequently show collateral sensitivity to antimicrobial peptides, a 
finding that can be utilized to identify peptide–antibiotic combina-
tions that effectively eradicate resistant bacteria and slow down the 
de novo evolution of resistance to antibiotics.
Methods
Medium, antimicrobial agents and strains used in the study. Antimicrobial 
peptides. Twenty-four cationic antimicrobial peptides were used in this study: 
SB006, HBD3, PROA, PR-39, PGLA, pexiganan (PEX), indolicidin (IND), BAC5 
and bactenecin 7 (BAC7), NCR335, magainin 2 (MAG), R8, D28, anginex (ANG), 
apidaecin IB, rabbit CAP18, pyrrhocoricin (PYR), pleurocidin (PLEU), synthetic 
cecropin-melittin hybrid (CEME), protegrin-1 (PRO1), polymyxin B (PXB), LL37, 
tachyplesin II (TPII) and CP1 (see also Supplementary Table 2). Antimicrobial 
peptides were custom synthesized by ProteoGenix, except for PROA and PXB, 
which were purchased from Sigma-Aldrich. The antimicrobial peptide solutions 
were prepared in sterile water and kept at − 80°C until usage.
Antibiotics. The following antibiotics were used in this study (see also 
Supplementary Table 1): chloramphenicol (CHL), TET, AMP, FOX, CPR, 
erythromycin (ERY), DOX, trimethoprim (TRM), TOB, KAN, NIT and NAL. 
Most of the antibiotics were purchased from Sigma-Aldrich, except for ERY 
(AMRESCO) and DOX (AppliChem). Fresh antibiotic solutions were  
prepared from powder stocks on a weekly basis, kept at − 20°C and filter  
sterilized before use.
Strains. E. coli K-12 BW25113 was used as the wild-type strain. The 60 laboratory-
evolved resistant strains, adapted to 12 different clinically relevant antibiotics (5 
evolved lines per antibiotic with the exception of AMP and NAL, for which 4 and 6 
replicates were used, respectively) were established in our previous work3. Briefly, 
the parallel-evolved populations reached up to 328-fold increases in the MICs 
relative to the ancestor. In all cases, the resistance levels were equal to or above 
the current clinical breakpoints according to EUCAST or the European Reference 
Laboratory for Antimicrobial Resistance. The evolution of multidrug resistance 
(resistance to two or more drugs) was frequent under a single antibiotic pressure: 
on average, 52% of all investigated antibiotic pairs showed cross-resistance in 
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at least one direction. Parallel-evolved lines were subjected to whole-genome 
sequencing to characterize the mutations responsible for multidrug resistance. On 
average, we detected 4.2 point mutations, 1.2 deletions, 0.26 insertions and 0.07 
duplications per clone. Details of the laboratory evolution experiments as well as 
the results of the whole-genome sequencing of the evolved strains are available in 
our previous works2,3.
The four E. coli single-mutant strains (envZ[Ala396Thr], ompC[Met1Ile], 
marR[Val84Glu], trkH[Thr350Lys]) were established using a highly precise allele 
replacement protocol described in our previous studies2,3,38. The sbmA single-gene 
deletion mutant was derived from the KEIO collection39. Both the wild-type and 
ompC[Met1Ile] strains were transformed with the waaY overexpression and the 
empty plasmids isolated from the ASKA (A complete set of E. coli K-12 Open 
Reading Frame Archive library) collection25.
The three E. coli uropathogen clinical isolates (0370, 3538, CFT073) before and 
after adaptation to three different antibiotics (gentamicin (GEN), NAL and AMP), 
the K. pneumoniae r1 (A) and the S. flexneri 668 clinical isolates and their NAL-
evolved strains were kindly provided by Morten Sommer, Technical University 
of Denmark, Hørsholm. Four CPR-resistant E. coli isolates, 1 to 4, were obtained 
from the local hospital and kindly provided by Edit Urbán, Department of Clinical 
Microbiology, University of Szeged, Hungary. Strains 1 to 3 were isolated from 
urine samples, while strain 4 was isolated from intraperitoneal punction. E. coli 
ATCC 25922, BAA 2469 and BAA 2340 strains were obtained from Microbiologics.
Medium. In line with previous, methodologically relevant laboratory evolution 
studies31,32,40, the physical conditions (including the medium) were the same 
during the course of laboratory evolution and all forthcoming assays on the 
resulting resistant lines. The logic is to minimize any potential confounding effects 
unrelated to adaptation to the antibiotic studied (that is, the only difference being 
the presence/absence of a given drug). Therefore, as a general rule, the same 
chemically defined medium and growth conditions were employed throughout 
the experiments in which the investigated antibiotic-resistant strains were evolved. 
This medium was optimized for a large set of antimicrobial peptides by decreasing 
the sodium citrate and the magnesium sulfate concentrations. This optimized 
medium was minimal salts medium (1 g l−1 (NH4)2SO4, 3 g l−1 KH2PO4 and 
7 g l−1 K2HPO4) supplemented with 0.1 mM MgSO4, 0.54 μ g ml−1 FeCl3, 1 μ g ml−1 
thiamine hydrochloride, 0.2% Cas amino acids and 0.2% glucose). Phosphate 
was available in the medium. This is important as scarcity of phosphate can 
modify the membrane composition and therefore the activity of antimicrobial 
peptides41,42. Unlike Muller–Hinton broth, the minimal salts medium used in our 
work is a chemically defined, highly controlled and reproducible environment, 
a characteristic that is particularly important in laboratory evolution and high-
throughput screenings. As an exception, note that Muller–Hinton II medium was 
used to study drug susceptibility of S. flexneri 668 strain, as this strain cannot 
grow in minimal salts medium. Reassuringly, the applied medium did not have an 
effect on the activity of PGLA when used as an adjuvant (see Supplementary Fig. 
10 where experiments with K. pneumoniae were done in minimal salts medium 
while the ones using S. flexneri were performed in Muller–Hinton II medium). All 
components were obtained from Sigma-Aldrich.
Systematic measurement of antimicrobial peptide susceptibilities. We aimed 
at detecting changes in the sensitivities of a large number of antibiotic-resistant 
strains compared to the wild-type strain towards a wide variety of antimicrobial 
peptides as well as bile acid. To this end, we developed a high-throughput 
screening and a robust statistical analysis methodology for the systematic detection 
of cross-resistance and collateral sensitivity interactions in E. coli. We compared 
the susceptibility of 60 antibiotic-resistant strains (5 evolved lines per antibiotic, 
established in our previous work3) to the wild-type strain across the entire set of 
antimicrobial peptides (n = 24) and bile acid (Fig. 1 and Supplementary Table 3). 
The three main steps of our methodology were (1) high-throughput measurement 
of growth inhibition of strains in liquid cultures in 96-well microtiter plates with 
the aim of detecting collateral-sensitive and cross-resistant phenotypes without 
precise MIC measurements (see below); (2) validation of the high-throughput 
results by standard MIC measurements on a subset of strain-peptide condition 
pairs and using receiver operating characteristic (ROC) curve analysis; (3) further 
validation of collateral sensitivity interactions at high antimicrobial peptide 
dosages using kill curve assays.
High-throughput estimation of collateral sensitivity and cross-resistance. To 
infer collateral sensitivity and cross-resistance interactions, we compared the 
growth sensitivity of antibiotic-resistant and wild-type strains by measuring 
their propensity to be arrested in growth by two specific dosages. In this screen, 
approximately 103 bacteria per ml were inoculated into each well of the 96-well 
microtiter plate with a 96-pin replicator, and were propagated at 30°C with shaking 
at 300 r.p.m. Bacterial growth was monitored by measuring absorbance 600 nm 
(A600 nm) of the liquid cultures at a single time point after 24 h of incubation in 
the presence of a given antimicrobial peptide. Growth arrest was defined as the 
failure to obtain growth at a given peptide concentration (that is, A600 nm was below 
the mean + 2 × s.d. of A600 nm values of bacteria-free wells containing only growth 
medium). In order to be able to discern condition-specific growth arrest from 
slow growth caused by a general cost of resistance, we chose an incubation time 
of 24 hours where all populations reached detectable growth in medium devoid of 
antimicrobial peptide. In order to maximize reproducibility and accuracy, a robotic 
liquid-handling system and an automatic incubator were used.
Antibiotic-resistant strains and wild-type strain were inoculated in 4 and 
12 replicate populations on the same 96-well plate, respectively. Growth arrest 
was determined for each of them and an inhibition score was calculated based 
on the replicate measurements as follows: Inhibition score = (NGAcontrol/12) - 
(NGAABstrain/4). NGA is the number of replicates showing growth arrest out of the 
12 control populations (NGAcontrol) or out of the 4 antibiotic-resistant populations 
(NGAABstrain). Two different peptide concentrations were chosen as one above 
(~1.2 × ) and one below (~0.8 × ) the MIC of the wild-type strain. The lower and 
the higher concentrations were applied to calculate inhibition score for collateral 
sensitivity and cross-resistance interactions, respectively. Specifically, to detect 
collateral sensitivity against a given peptide, we tested whether a peptide dosage 
below the wild-type MIC (0.8× ) fully inhibits growth of a particular antibiotic-
resistant strain, but not the wild-type. To detect cross-resistance, we applied a 
peptide dosage somewhat above the wild-type MIC (1.2× ), and asked whether 
antibiotic-resistant strains can grow. We conducted at least four independent 
experimental runs for each combination of strains and peptide conditions. Next, to 
filter out unreliable measurements for the detection of cross-resistance/collateral 
sensitivity interactions, we excluded cases where (1) cross-contamination might 
have occurred on the plate during susceptibility measurements (based on growth 
in non-inoculated wells), (2) the control wells devoid of peptide showed large 
variations (coefficient of variation was above 20%), (3) in the case of collateral 
sensitivity interactions where the applied dosages were too high and arrested the 
growth of more than 50% of the control populations and (4) in the case of cross-
resistance interactions where the applied dosages were too low and only arrested 
the growth of less than 50% of the control populations. This quality control 
procedure resulted in 2–4 replicates for each combination of strains and peptide 
conditions. Then, we calculated the average of the inhibition score derived from 
the multiple independent experimental runs, and defined cut-off values of the 
inhibition score to detect cross-resistance and collateral sensitivity interactions, 
respectively (see below).
To define a robust cut-off value on the inhibition score, we first performed a 
detailed analysis of MIC on a subset of strain-peptide condition pairs (n = 110) 
(Supplementary Table 4). Each antibiotic-resistant strain was characterized as to 
show cross-resistance or collateral sensitivity to a certain antimicrobial peptide 
if it showed at least 20% difference in its MIC value compared to the wild-type 
strain. Next, we chose an inhibition score threshold that maximized the fit 
between the results of the high-throughput susceptibility screen and those of the 
traditional MIC measurements. The fit between the two datasets was defined as 
the area under the ROC curve calculated from the inhibition score of the high-
throughput susceptibility screen and the collateral sensitivity/cross-resistance 
classification of the detailed MIC measurements. The area under the ROC curve 
(AUC) is a measure of how well the inhibition score can distinguish between cross-
resistance/collateral sensitivity interactions and the absence of interactions. The 
calculated AUC was 0.89 and 0.93 for the collateral sensitivity and cross-resistance 
interactions, respectively. A random classifier has an AUC of 0.5, while AUC for a 
perfect classifier is equal to 1. The cut-off point of the inhibition score was chosen 
as the value that minimizes the Euclidean distance between the ROC curve and the 
optimum point of the graph (true positive rate = 1, false positive rate = 0).
MIC measurements. MICs were determined using a standard serial broth dilution 
technique43. In order to maximize reproducibility and accuracy, we used a 
robotic liquid-handling system to prepare 12-step serial dilutions automatically 
in 96-well microtiter plates. In case of determination of relative MIC involving 
the measurement of small changes, 1.15–1.5-times dilutions were used, and 
approximately 104 bacteria per ml were inoculated into each well using a 96-pin 
replicator and were propagated at 30°C with shaking at 300 r.p.m. (3 replicates 
per strain per antimicrobial peptide concentration). This protocol was previously 
established with the aim of identifying small changes in relative MICs in a high-
throughput and reproducible manner2,3. Otherwise, experiments on the impact 
of PGLA co-treatment of antibiotic-resistant levels or determination of antibiotic 
and peptide MIC levels upon evolution of resistance used 2-times dilutions and an 
inoculum of 5 × 105 bacteria per ml as suggested by the Clinical and Laboratory 
Standards Institute (CLSI) guidelines. To avoid possible edge effects, rows A and 
H contained only media devoid of cells. The environment during incubation was 
also set to minimize evaporation and hence edge effects. After 24 h of incubation at 
30°C, raw A600 nm values were measured in a Biotek Synergy microplate reader. MIC 
was defined by a cutoff A600 nm value (mean + 2 s.d. of A600 nm values of bacteria-free 
wells containing only growth medium). Relative MIC was calculated as follows: 
MICrelative = MICABresistant / MICcontrol.
Kill curve assay. Tolerance of antibiotic-resistant strains to antimicrobial peptides 
was measured by determining changes in population size upon exposure to lethal 
concentrations of PGLA (15 × MIC), PROA (15 × MIC), IND (10 × MIC) in the 
wild-type, various antibiotic-resistant and single-mutant strains. The experiments 
were conducted in 96-deep well plates (1,000 µ l medium supplemented with the 
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peptide). Each well initially contained approximately 106 cells. During antibiotic 
treatment, three samples were taken at multiple time points (0, 15, 30, 60, 90  
and 120 minutes postexposure) from each three parallel populations per strain. 
The total number of viable cells (colony forming units) was estimated from colony 
counts after plating the diluted cells on agar plates and incubating them  
for 24 hours.
Membrane integrity measurements. Membrane integrity of the antibiotic-
resistant strains was investigated by measuring their sensitivity to the amphipathic 
LPS and outer membrane-related genes-damaging agent bile acid (see Methods: 
High-throughput estimation of collateral sensitivity and cross-resistance). 
Antibiotic-resistant strains were then grouped by their sensitivity to bile acid: 
sensitive strains could not grow on medium supplemented with 6% bile acid 
while non-sensitive strains were able to grow on this concentration. We compared 
the number of antibiotic-resistant strains that showed collateral sensitivity to 
antimicrobial peptides between the above two groups (Fig. 3a). Because the 
number of antibiotic-resistant strains qualifies as count data, we assessed statistical 
significance in this comparison using a generalized linear mixed model (GLMM) 
with binomial response distributions and logit link functions as implemented 
in the R package 'lme4'44. We note that the variable representing the number of 
antibiotic-resistant strains was set as an observational-level random effect to 
account for overdispersion45.
Total RNA isolation. Total RNA was extracted, as described previously46, 
from samples grown in minimal medium devoid of any antibiotic to ensure 
comparability of strains that show vastly different resistance levels across 
antibiotics. Samples were collected in log-phase growth (A600 nm ≈ 0.5 for RT–
PCR experiments and A600 nm ≈ 1 for RNA sequencing) applying the QIAGEN 
RNA Protect bacteria reagent and stored at − 80°C until RNA isolation. RNA 
isolation was performed using NucleoSpin RNA extraction kit (Macherey-Nagel) 
according to the manufacturer’s protocol. Purity of total RNA was determined 
as 260 nm/280 nm absorbance ratio with expected value of 2.0 by the NanoDrop 
1000 spectrophotometer (Thermo Scientific). RNA integrity was confirmed by gel 
electrophoresis using 1% agarose with GelRed staining. Total RNA was DNase I 
treated by Ambion DNase I to eliminate residual genomic DNA.
Whole transcriptome sequencing and data analysis. Whole transcriptome 
sequencing was performed on 24 antibiotic-resistant strains (2 strains per 
antibiotic, 3 biological replicates per strain) as described previously47. The reference 
genome sequence (U00096.3) as well as genome annotation data were downloaded 
from the EcoGene 3.0 database (http://www.ecogene.org/)48 for E. coli strain K-12 
MG1655. Raw sequence data were size-selected by discarding reads shorter than 
50 base pairs (bp). This filtering was applied to ensure maximum read quality 
and consistent read mapping parameters. CLC Genomic Workbench tool version 
7.5.1 (CLC Bio now part of Qiagen) was used to obtain gene expression estimates 
(mapped read counts) for each annotated gene in all samples using the following 
CLC RNA-Seq analysis parameters: the maximum number of mismatches  
was set to 2 with minimum length and similarity fractions both set to 0.8 and 
unspecific match hit set to 10. It is important to note that the applied alignment 
length parameter is expressed as a fraction of the raw read length. This could 
result in a more permissive mapping for shorter reads. In order to ensure the 
same mapping stringency for all reads, we decided to exclude reads shorter than 
50 bp. Please also note that the excluded short raw read fraction is generated by 
the SOLiD analysis pipeline due to the removal of low quality read parts. SOLiD 
low quality readouts, as well as the resulting short reads, are expected to appear 
randomly within the sequencing run. That way, the removal of reads shorter 
than 50 bp is not expected to cause any bias in the subsequent differential gene 
expression analysis. Read count data were then imported into R version 3.0.249 
excluding ribosomal DNA (rDNA) genes. Genes were filtered based on their 
expression levels, keeping only those features that were detected by at least five 
mapped reads in at least 25% of the samples included in the study. Subsequently, 
'calcNormFactors' from package 'edgeR' version 3.4.250 was used to perform 
data normalization based on the 'trimmed mean of M-values' method51. Log 
transformation and quantile normalization was carried out by the 'voom' function 
of the 'limma' package version 3.18.152. 'ComBat' tool from the 'sva' package version 
3.8.053 was applied to correct for systematic batch effects that were caused by 
growing subsets of the samples in separate batches. Linear modelling, empirical 
Bayes moderation and calculation of differentially expressed genes were carried  
out using 'limma'.
The selection of differentially expressed genes was based on the comparison of 
the normalized counts per read of the control and the antibiotic-resistant strains. 
Genes with significant differences (false-discovery rate corrected P values < 0.05) 
and with fold change (FC) greater than a chosen threshold (|log2(FC)| > 1) were 
regarded as differentially expressed. The log2 fold change values of the normalized 
expression data and the false-discovery rate corrected P values are provided in 
Supplementary Table 8. Finally, we note that although obtaining RNA samples at 
A600 nm ≈ 1 may be close to stationary phase, the inferred differential expressions of 
LPS and phospholipid-related genes are unlikely to be byproducts of the applied 
RNA sample extraction condition. Specifically, our conclusions remain after 
excluding genes with potential stationary phase dependent expression from our 
analyses (see Supplementary Fig. 15). The set of stationary phase regulated genes 
(N = 449) was compiled from literature54–56 and by identifying those genes in our 
dataset whose expression level was significantly correlated (P < 0.05) with A600 nm at 
the time of sample collection in our experiments.
The transcriptome data can be accessed from the Gene Expression Omnibus 
repository (https://www.ncbi.nlm.nih.gov/geo/) with the following access  
number: GSE96706.
Functional analyses of differentially expressed genes. To obtain a detailed 
functional annotation of the genes associated with outer membrane LPS and 
phospholipid synthesis, we selected the following gene ontology categories: lipid-A 
biosynthetic process (GO:0009245), extracellular polysaccharide biosynthetic 
process (GO:0045226), LPS biosynthetic process (GO:0009103), LPS core region 
biosynthetic process (GO:0009244), LPS transport (GO:0015920), phospholipid 
transport (GO:0015914) and phospholipid binding (GO:0005543). The selection 
was based on EcoGene 3.0 database48.
The category ‘All LPS-related genes’ includes all the genes that are associated 
with at least one of the following gene ontology categories: lipid-A biosynthetic 
process, extracellular polysaccharide biosynthetic process, LPS biosynthetic 
process, LPS core region biosynthetic process and LPS transport. The category 
‘All Phospholipid-related genes’ includes all the genes that are associated with 
phospholipid transport or phospholipid binding gene ontology categories. Further 
information about the full gene sets is provided in Supplementary Table 9.
To investigate the upregulated LPS-related genes in more detail, we performed 
Fisher’s exact tests on all resistant strains and all subcategories of LPS-related 
genes (Fig. 3c, left heatmap). In addition, Student’s t-tests were used to identify 
differences in the average gene expression in a given gene ontology category 
among antibiotic-resistant strains grouped according to their antimicrobial peptide 
sensitivity (Fig. 3c, right heatmap, Supplementary Fig. 5).
Chemogenomic screen. Competition experiment. A high-throughput gene 
overexpression screen was performed to study the impact of upregulating each 
E. coli ORF on the susceptibility to a particular antimicrobial peptide (CAP18 
and CP1). For a schematic workflow see Supplementary Fig. 6a. The screen was 
carried out using a well-established plasmid library (ASKA), where each E. coli 
ORF is cloned into a high copy number expression plasmid (pCA24N-ORF-
GFP(-))25. A previously described, pooled version of the plasmid collection57 was 
transformed into E. coli K-12 BW25113 strain by electroporation, as well as the 
empty plasmid pCA24N (without an ORF). The empty plasmid serves as a control 
to measure read counts that come from genomic DNA contamination during 
plasmid preparation (background). The resulting strain collection and the strain 
carrying the empty plasmid were grown in parallel in minimal salts medium 
and expression of the ORFs was induced mildly with a relatively low inducer 
concentration (100 µ M isopropyl-ß-D-thiogalactopyranoside). Following 1 h of 
incubation at 30°C, 500,000 cells from the library were used to inoculate each well 
of a 96-well microtiter plate prefilled with a concentration gradient of the peptide 
in minimal salts media supplemented with 10 µ g ml−1 CHL and 100 µ M isopropyl-
ß-D-thiogalactopyranoside, the same way as for a standard MIC measurement 
(described above). As a further control, both the library and the empty plasmid 
were also grown in the absence of peptide. Growth was monitored in a microplate 
reader (Biotek Synergy 2). Wells that showed 50% growth inhibition in late log 
phase were transferred into 20 ml minimal salts medium supplemented with 
the corresponding peptide. Peptide concentration was set again to result in 50% 
growth inhibition. Growth was stopped at late log phase (A600 nm > 1). Following 
plasmid isolation, the samples were digested overnight with a mixture of lambda 
exonuclease and exonuclease I (Fermentas) at 37°C to remove genomic DNA 
contamination. The cleaned samples were subjected to next-generation sequencing 
with the SOLiD System (Life Technologies) to determine the diversity of the pooled 
library as described previously57. Each treatment was carried out in two replicates, 
except the untreated sample (in the absence of peptide), which had five replicates. 
The experiment with the empty plasmid was also carried out twice.
Data analysis. Raw sequence data processing and mapping onto E. coli ORFs 
were carried out the same way as in the whole transcriptome analysis. Raw 
sequence data were also mapped to the plasmid backbone. In order to make the 
mapped read counts comparable between the different samples, we carried out 
the following data processing workflow based on established protocols58,59, using 
a custom made R script: The extra read counts coming from the genomic DNA 
contamination (background) were estimated by assuming that the reads mapping 
to the unit length of the plasmid and the ORFs should have a ratio of 1:1. The 
total extra read count estimated thereof was partitioned among the ORFs based 
on their background frequency (that is, their relative frequency obtained from the 
experiment involving the empty plasmid). Next, these ORF-specific backgrounds 
were subtracted from the read counts. Then, a loglinear transformation was carried 
out on the background-corrected relative read counts. This transformation has 
the advantage over canonical logarithmic transformation of avoiding the inflation 
of data variance for ORFs with very low read counts60. The transformed relative 
read counts showed bimodal distributions (Supplementary Fig. 6b,c). The lower 
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mode (peak) of the distribution corresponds to ORFs that were not present in 
the sample. The upper mode represents those ORFs that grew unaffected by the 
overexpression. To make the different samples comparable, the two modes of the 
distribution of each sample were set to two predefined values. These values were 
chosen such that the original scale of the data was retained. In order to align the 
modes between samples, we introduced two normalization steps: one before and 
one after the loglinear transformation. The first normalization step identified 
the lower mode corresponding to the absent strains and shifted it to zero. Next, 
we performed the loglinear transformation step described above. The second 
normalization step was a linear transformation moving the upper mode to a 
higher predefined value. Following this normalization step, genes that were close 
to the lower mode in the untreated samples were discarded from the analysis as 
these represent strains that displayed poor growth even in the absence of drug 
treatment (that is, antimicrobial peptide sensitivity could not be reliably detected). 
Differential growth was calculated as the ratio of the normalized relative read 
counts in the treated and the non-treated samples at the end of the competition. 
Genes showing at least a twofold decrease in relative abundance in both replicates 
upon peptide treatment were considered as sensitizing genes.
In the next step, we examined the enrichment of CAP18- and CP1-sensitizing 
genes (Supplementary Table 10) in various gene ontology categories using 
Fisher’s exact test. Obtained P values were corrected for multiple testing using the 
Benjamini & Hochberg method61 (Supplementary Table 11).
Real-time PCR analysis. The waaY gene expression of the wild-type and 
marR mutant strains was determined by real-time RT–qPCR as described 
previously38. Briefly, quantitation of cysG expression level was applied as a 
reference standard across both samples62. RT–qPCR was performed in a Bio-Rad 
CFX96 Real Time System (Bio-Rad Laboratories). The PCR mixtures consisted 
of ~300 ng total RNA sample, 0.1 μ M waaY_FW-waaY_REV primer pair 
(5’-ATCGATCTCTCCGGAAAGC, 5’-CCTTTCAAACGCCGCATA) or 0.1 μ M 
cysG_FW-cysG_REV reference primer pair (5’-TTGTCGGCGGTGGTGATGTC, 
5’-ATGCGGTGAACTGTGGAATAAACG)62 and Verso one-step RT–qPCR Master 
Mix with low ROX reference dye (Thermo Scientific) in a final volume of 25 μ l. 
The assay included 'non-template' and 'non-reverse transcription' controls to detect 
reagent contamination and presence of genomic DNA. The reverse transcription 
reaction was performed at 50°C for 15 min and the thermal profile of the PCR 
procedure repeated for 40 cycles was: 95°C for 10 min, 20 s denaturation at 95°C, 
20 s annealing at 60°C and 60 s at 72°C coupled to data collection at the end of each 
amplification step. The dissociation curve consisted of 10 s incubation at 95°C, 
5 s incubation at 65°C and ramp up to 95°C. Melting curves were used to validate 
product specificity. All samples were amplified in triplicate from the same total 
RNA preparation and the mean value was used for further analysis. Cycle threshold 
(Ct) values were determined using Bio-Rad CFX96 software.
The waaY expression level was calculated by relative messenger RNA 
quantitation, based on the mean of technical replicates, normalized to the 
expression level of the cysG control and taking into consideration the efficiency 
level of each primer pair. Each primer efficiency (E) was determined as 
E = 10−1/slope− 1, based on the slope of four point standard curves with ten times 
concentration intervals, in duplicate, using wild-type strain RNA. Efficiency of 
waaY and cysG primer pairs was determined as 1.6 and 1.8, respectively. waaY 
expression level in the marR mutant strain was calculated relative to that of the 
wild-type strain as follows: Expression level = (1.6(CtwaaY_WT-CtwaaY_marR*)/ 
(1.8(CtcysG_WT)-(CtcysG_marR*)), and is presented as the mean of triplicates ± s.e.m.
Measurement of antibiotic and PGLA combinations. We selected PGLA 
antimicrobial peptide, which interacts with the bacterial LPS layer, and ten 
different antibiotics with a wide range of mechanisms of action (Supplementary 
Table 1). All experiments were conducted in the antibiotic-sensitive wild-type E. 
coli K-12 (BW25113) strains and in 21 different antibiotic-resistant strains adapted 
to 1 of 10 antibiotics (established in our previous work3) (Supplementary Table 12). 
Combination screens were performed in 96-well plates, using a liquid-handling 
robotic system (Hamilton Star workstation) to improve reproducibility.
Interactions between the two drugs were classified as synergistic, independent 
(additive) or antagonistic based on growth measurements at multiple concentration 
combinations (see below). Drug interaction was defined as deviation from non-
interaction under the Loewe additivity model63, which assumes that a drug does 
not interact with itself. We followed a previously published protocol64 with two 
important modifications. First, instead of examining all pairwise combinations of 
a predefined number of linearly increasing concentration points, we focused on 
a set of different antibiotic-PGLA relative concentration ratios and their dilution 
series (see Supplementary Fig. 16). This setup enabled us to efficiently sample the 
most informative regions of the two-dimensional concentration space. Second, we 
inferred drug interactions based on concentration combinations that led to 90% 
growth inhibitions (Supplementary Fig. 16). This enabled an especially robust 
detection of growth inhibition for antimicrobial peptides, which often exhibit steep 
dose-response curves that hinder precise measurement of, say, 50% inhibition 
concentrations.
As a first step, for each single agent (antibiotic and peptide alike), a 1.6-fold, 
eight-step dilution series was prepared with dose points determined based on the 
MIC of the agents. The concentration range for each agent was between 10.5 times 
lower and 2.6 times higher than the MIC of the strain. Then, for each antibiotic-
peptide pair we set up a 96-well plate as follows: we defined 7 different antibiotic/
peptide relative concentration ratios (7:1, 3:1, 5:3, 1:1, 3:5, 1:3, 1:7) and generated 
dilution series thereof across the plate. As a result, each plate contained dilution 
series of seven antibiotic/peptide ratios, dilution series from the given antibiotic  
or peptide alone, four bacteria-free wells (no growth control) and four  
wells containing only medium without any drugs (growth control)  
(see Supplementary Fig. 16a).
Combination screen plates were inoculated with 5 × 104 cells per well from 
overnight culture (grown at 30°C, with shaking at 300 rpm). The culture volume 
was 100 μ l. Assay plates were incubated at 30°C with shaking at 300 rpm and 
bacterial growth was monitored by measuring the A600 nm of the liquid cultures 
after 24 h. We chose an incubation time of 24 hours in order to be able to discern 
condition-specific fitness defects from general costs of resistance of the antibiotic-
resistant strains.
Identifying interactions between antibiotics and PGLA. To assess antagonism and 
synergy between pairs of antibiotics and PGLA in the sensitive wild type and in  
the antibiotic-resistant strains, we used the Loewe additivity model63 which 
assumes that a drug does not interact with itself. To identify interactions for  
each pair of antibiotics and PGLA we first calculated relative inhibition values 
based on the initial A600 nm (maximum inhibition) and the average A600 nm of 
antibiotic-free control wells (maximum growth). Then, we identified those two 
concentration points for each antibiotic/peptide ratio where the inhibition of 
the growth was just above and below 90%, respectively. By fitting a linear model 
between these two concentration points we could interpolate the dosages for  
each antibiotic/peptide ratio that were responsible for the 90% growth inhibition 
(90% effective dosage: EC90%). Based on the Loewe model from the EC90% values 
of the single agents, we then calculated the theoretical EC90% dosages for each of 
the seven antibiotic/peptide ratios. Geometrically, the theoretical EC90% based on 
the Loewe model can be represented as a straight line between the EC90% of the 
single agents in the two-dimensional linear concentration space. Deviation of the 
shape of the lines connecting the experimentally measured EC90% from linearity 
indicates either synergy (concave isoboles) or antagonism (convex isoboles) 
(Supplemetary Fig. 12). For each of the seven antibiotic/peptide ratios we defined 
the expected and the experimentally measured EC90% values. The combination 
index was calculated as: (theoretical EC90%)/(experimental EC90%) for each 
antibiotic/peptide ratio (CIr). The combination index for a given antibiotic and 
peptide pair was defined as the average of the combination index of the seven 
antibiotic/peptide ratios (mean(CIr1,CIr2… CIr7)). Where multiple independent 
experimental runs were available, we calculated the average value of the measured 
combination indexes.
Measurement errors of interaction screens were estimated from two 
independent experimental runs of 24 combinations by calculating the pooled 
variance (standard deviation) of the combination indexes of the replicate 
experiments. The cut-off values were defined as 1.95 × s.d. value of the 
combination index. The cut-off values were as follows: combination index ≥ 1.14 
for antagonism; combination index ≤ 0.86 for synergism; and 0.86 < combination 
index < 1.14 for no interaction.
Experimental evolution of resistance. Experimental evolution was performed 
based on a previously established automated evolution experiment65,66 during 
approximately 160 generations (24 transfers). Ten parallel independent cultures 
were propagated in eight experimental conditions such as TET or CPR in the 
presence or absence of ½ and ¼ of the MIC of PGLA; TOB in the presence or 
absence of ½ and ¼ of the MIC of the BAC5; as well as ½ and ¼ of the MIC of 
PGLA and ½ and ¼ of the MIC of BAC5, alone. Chess-board layout was used 
on the plate to monitor potential cross-contamination events. Starting with 
subinhibitory drug concentration, each culture was allowed to grow for 24 hours. 
Twenty microlitres of culture was transferred to four independent wells containing 
fresh medium and increasing dosages of antibiotic (0.5 × , 1 × , 1.5 × and 2.5 × the 
concentration of the previous step). At each transfer, cell growth was monitored 
by measuring the A600 nm value (Biotek Synergy 2 microplate reader was used for 
this purpose). Only populations of the highest drug concentration that reached 
A600 nm > 0.2 were selected for further evolution. Accordingly, only one of the four 
populations was retained for each independently evolving lineage. This protocol 
was designed to avoid population extinction and to ensure that populations with 
the highest level of resistance were propagated further during evolution.
Reporting Summary. Further information on experimental design is available in 
the Nature Research Reporting Summary linked to this article.
Data availability. The transcriptome data can be accessed from the Gene 
Expression Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/) with access 
number GSE96706.
The following excel files are provided as supplementary items in separated files:
Supplementary Table 2 – The list of antimicrobial peptides employed in this 
study and the available information about them based on literature mining.
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Supplementary Table 3 – Dataset of collateral sensitivity and cross-resistance 
interactions identified at the level of antibiotic-resistant strains.
Supplementary Table 4 – Relative changes in the minimum inhibitory 
concentrations (MIC) of the antimicrobial peptides towards antibiotic-resistant 
strains.
Supplementary Table 6 – List of the main chemical and physical properties of 
the antimicrobial peptides employed in this study.
Supplementary Table 7 – Susceptibility profiles of antibiotic-resistant E. coli 
clinical isolates across antimicrobial peptides.
Supplementary Table 8 – Differential expression analysis of RNA-Seq data of 24 
antibiotic-resistant strains.
Supplementary Table 9 – Bile acid sensitivity of the antibiotic-resistant strains 
and list of genes involved in phospholipid and LPS synthesis.
Supplementary Table 10 – List of genes sensitizing towards CAP18 and CP1 in 
the chemogenomic study but not to control peptide CP1.
Supplementary Table 13 – Combination index (CI) values of PGLA–antibiotic 
(AB) combinations on E. coli clinical isolates and respective antibiotic-resistant 
strains.
Supplementary Table 14 – Mutation-incorporating pORTMAGE 
oligonucleotides, allele-specific colony-PCR, HRM PCR and sequencing primers.
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